Sareum released a trading update on 19 August ahead of its full-year results (financial year end 30 June 2021) expected in October 2021. Final pre-clinical studies on the lead asset, TYK2/JAK1 inhibitor SDC-1801, are now expected to commence in Q421 (previously Q321) due to COVID-19 induced supply disruptions. The timeline for the clinical trial application (CTA) and Phase I clinical trials, however, remains unchanged (end Q421 and early 2022 respectively). Short-term liquidity issues have been ....
20 Aug 2021
Sareum Holdings - Fund raising to cushion pipeline risk
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sareum Holdings - Fund raising to cushion pipeline risk
Sareum Holdings plc (SAR:LON) | 11.0 -0.4 (-24.1%) | Mkt Cap: 7.89m
- Published:
20 Aug 2021 -
Author:
Jyoti Prakash -
Pages:
3
Sareum released a trading update on 19 August ahead of its full-year results (financial year end 30 June 2021) expected in October 2021. Final pre-clinical studies on the lead asset, TYK2/JAK1 inhibitor SDC-1801, are now expected to commence in Q421 (previously Q321) due to COVID-19 induced supply disruptions. The timeline for the clinical trial application (CTA) and Phase I clinical trials, however, remains unchanged (end Q421 and early 2022 respectively). Short-term liquidity issues have been ....